11 May 2016 - Bristol-Myers Squibb and AbbVie announced today that the European Commission has approved Empliciti (elotuzumab) for the treatment of multiple myeloma as combination therapy with Revlimid (lenalidomide) and dexamethasone in patients who have received at least one prior therapy.

Empliciti is now the first and only immunostimulatory antibody approved for multiple myeloma in the EU.

For more details, go to: http://news.bms.com/press-release/bmy/bristol-myers-squibb-and-abbvie-announce-european-commission-approval-empliciti-el